ALVO trades 148.6% below Wall Street's consensus target of $8.60.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ALVO achieves its forward estimates and maintains a stable P/E multiple of 44.2x. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, Alvotech (ALVO) has a Wall Street consensus price target of $8.60, based on estimates from 5 covering analysts. With the stock currently trading at $3.46, this represents a potential upside of +148.6%. The company has a market capitalization of $1.16B.
Analyst price targets range from a low of $5.00 to a high of $10.00, representing a 58% spread in expectations. The median target of $10.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, ALVO trades at a trailing P/E of 34.6x and forward P/E of 44.2x. Analysts expect EPS to grow +132.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
AMGNAmgen Inc. | $197.8B | $366.44 | $352.50 | -3.8% | Buy | 16.4x | 38 |
TEVATeva Pharmaceutical Industries Limited | $38.9B | $33.44 | $40.00 | +19.6% | Buy | 15.9x | 46 |
VTRSViatris Inc. | $19.6B | $16.80 | $17.40 | +3.6% | Hold | 6.8x | 13 |
ABBVAbbVie Inc. | $450.1B | $254.76 | $258.00 | +1.3% | Buy | 17.9x | 41 |
JNJJohnson & Johnson | $624.3B | $259.33 | $253.42 | -2.3% | Buy | 22.4x | 40 |
PFEPfizer Inc. | $134.9B | $23.72 | $26.75 | +12.8% | Hold | 8.0x | 39 |
BIIBBiogen Inc. | $30.8B | $208.46 | $218.32 | +4.7% | Buy | 14.4x | 48 |
REGNRegeneron Pharmaceuticals, Inc. | $67.5B | $649.81 | $836.00 | +28.7% | Buy | 14.0x | 48 |
MRKMerck & Co., Inc. | $313.1B | $126.78 | $133.77 | +5.5% | Buy | 24.7x | 37 |
MCKMcKesson Corporation | $94.3B | $784.23 | $994.86 | +26.9% | Buy | 17.7x | 31 |
Quick answers to the most common questions about buying ALVO stock.
The consensus Wall Street price target for ALVO is $8.6, representing 148.6% upside from the current price of $3.46. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ALVO has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is mixed, with 2 Hold ratings making up the largest segment. The consensus 12-month price target of $8.6 implies 148.6% upside from current levels.
At a forward P/E of 44.2455x, ALVO trades at a premium valuation. The consensus price target of $8.6 (148.6% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $10 for ALVO, while the most conservative target is $5. The consensus of $8.6 represents the median expectation. These targets typically reflect 12-month expectations.
ALVO is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 2 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ALVO stock forecast based on 5 Wall Street analysts shows a consensus price target of $8.6, with estimates ranging from $5 (bear case) to $10 (bull case). The median consensus rating is "Buy".
ALVO trades at a forward P/E ratio of 44.2x based on next-twelve-months earnings estimates compared to a trailing P/E of 34.6x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on ALVO, with a "Buy" consensus rating and $8.6 price target (148.6% upside). 2 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ALVO analyst price targets range from $5 to $10, a 58% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $8.6 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.